Merck & Co. (MRK) : Duff Phelps Investment Management Co reduced its stake in Merck & Co. by 2.11% during the most recent quarter end. The investment management company now holds a total of 35,273 shares of Merck & Co. which is valued at $2,191,864 after selling 760 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Oct 14, 2016.Merck & Co. makes up approximately 0.03% of Duff Phelps Investment Management Co’s portfolio.
Other Hedge Funds, Including , Charter Trust Co boosted its stake in MRK in the latest quarter, The investment management firm added 1,227 additional shares and now holds a total of 162,607 shares of Merck & Co. which is valued at $10,104,399. Merck & Co. makes up approx 1.17% of Charter Trust Co’s portfolio.Community Bank N.a. reduced its stake in MRK by selling 703 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 97,801 shares of MRK which is valued at $6,113,541. Merck & Co. makes up approx 1.42% of Community Bank N.a.’s portfolio.First National Bank Of Omaha reduced its stake in MRK by selling 360 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 50,693 shares of MRK which is valued at $3,139,417. Merck & Co. makes up approx 0.25% of First National Bank Of Omaha’s portfolio.Hills Bank Trust Co reduced its stake in MRK by selling 5,735 shares or 41.91% in the most recent quarter. The Hedge Fund company now holds 7,950 shares of MRK which is valued at $508,005. Merck & Co. makes up approx 0.18% of Hills Bank Trust Co’s portfolio.New England Research Management reduced its stake in MRK by selling 24,202 shares or 63.48% in the most recent quarter. The Hedge Fund company now holds 13,922 shares of MRK which is valued at $874,302. Merck & Co. makes up approx 0.74% of New England Research Management’s portfolio.
Merck & Co. closed down -0.37 points or -0.59% at $62.14 with 1,22,04,208 shares getting traded on Friday. Post opening the session at $62.72, the shares hit an intraday low of $62.13 and an intraday high of $62.86 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Merck & Co. was Upgraded by BofA/Merrill to ” Buy” on Oct 13, 2016. Company shares were Reiterated by Barclays on Sep 9, 2016 to “Overweight”, Firm has raised the Price Target to $ 72 from a previous price target of $66 .Credit Suisse Upgraded Merck & Co. on Aug 8, 2016 to ” Outperform”, Price Target of the shares are set at $73.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.